The Global Companion Diagnostics Market size is expected to reach $6.5 billion by 2025, rising at a market growth of 19.9% CAGR during the forecast period.
A companion diagnostics test is done to understand which patient can gain benefits from a specific drug or decide upon the kind of dosage that should be prescribed. All of this, on the basis of a patient's clinical diagnosis, which offers required evidence for the successful and harmless utilization of an equivalent biological or drug product to treat the medical issue. These can also be referred to as medical instruments that help doctors in electing which dosage or treatment is sufficient for patients and suits to their necessity.
The growth of research and development activities in the genetic sciences and biomarkers leads to new drug development mechanisms, dominated by companion diagnostics in the personalized medicine phase. Moreover, the development and usage of companion diagnostics have considerably improved the knowledge of the molecular causes of illnesses, the identification of many biomarkers and the development of targeted treatment.
Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
Scope of the Study
Market Segmentation:
By Technology
- Immunohistochemistry
- Polymerase chain reaction (PCR)
- Next generation sequencing (NGS)
- In Situ Hybridization and
- Other Technology
By Indication
- Oncology
- Neurology and
- Other Indications
By Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer and
- Other Cancer Type
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled:
- Agilent Technologies, Inc.
- Almac Group
- ARUP Laboratories, Inc.
- Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- Hologic, Inc.
- Novartis AG
- Illumina, Inc.
- Qiagen N.V.
Unique Offerings from KBV Research:
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Companion Diagnostics Market, by Technology
- 1.4.2 Global Companion Diagnostics Market, by Indication
- 1.4.3 Global Companion Diagnostics Market, by Cancer Type
- 1.4.4 Global Companion Diagnostics Market, by Geography
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.2 Executive Summary
- 2.1.3 Market Composition and Scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Global Companion Diagnostics Market by Technology
- 3.1 Global Immunohistochemistry Market by Region
- 3.2 Global Polymerase chain reaction (PCR) Market by Region
- 3.3 Global Next generation sequencing (NGS) Market by Region
- 3.4 Global In Situ Hybridization Market by Region
- 3.5 Global Other Technology Market by Region
Chapter 4. Global Companion Diagnostics Market by Indication
- 4.1 Global Oncology Companion Diagnostics Market by Region
- 4.2 Global Companion Diagnostics Market by Cancer Type
- 4.2.1 Global Breast Cancer Companion Diagnostics by Region
- 4.2.2 Global Colorectal Cancer Companion Diagnostics by Region
- 4.2.3 Global Lung Cancer Companion Diagnostics by Region
- 4.2.4 Global Blood Cancer Companion Diagnostics by Region
- 4.2.5 Global Other Cancer Type Companion Diagnostics Market by Region
- 4.3 Global Neurology Companion Diagnostics Market by Region
- 4.4 Global Other Indications Companion Diagnostics Market by Region
Chapter 5. Global Companion Diagnostics Market by Region
- 5.1 North America Companion Diagnostics Market
- 5.1.1 North America Companion Diagnostics Market by Technology
- 5.1.1.1 North America Immunohistochemistry Market by Country
- 5.1.1.2 North America Polymerase chain reaction (PCR) Market by Country
- 5.1.1.3 North America Next generation sequencing (NGS) Market by Country
- 5.1.1.4 North America In Situ Hybridization Market by Country
- 5.1.1.5 North America Other Technology Market by Country
- 5.1.2 North America Companion Diagnostics Market by Indication
- 5.1.2.1 North America Oncology Companion Diagnostics Market by Country
- 5.1.2.2 North America Neurology Companion Diagnostics Market by Country
- 5.1.2.3 North America Other Indications Companion Diagnostics Market by Country
- 5.1.3 North America Companion Diagnostics Market by Cancer Type
- 5.1.3.1 North America Breast Cancer Companion Diagnostics by Country
- 5.1.3.2 North America Colorectal Cancer Companion Diagnostics by Country
- 5.1.3.3 North America Lung Cancer Companion Diagnostics by Country
- 5.1.3.4 North America Blood Cancer Companion Diagnostics by Country
- 5.1.3.5 North America Other Cancer Type Companion Diagnostics Market by Country
- 5.1.4 North America Companion Diagnostics Market by Country
- 5.1.4.1 USA Companion Diagnostics Market
- 5.1.4.1.1 USA Companion Diagnostics Market by Technology
- 5.1.4.1.2 USA Companion Diagnostics Market by Indication
- 5.1.4.2 Canada Companion Diagnostics Market
- 5.1.4.2.1 Canada Companion Diagnostics Market by Technology
- 5.1.4.2.2 Canada Companion Diagnostics Market by Indication
- 5.1.4.3 Mexico Companion Diagnostics Market
- 5.1.4.3.1 Mexico Companion Diagnostics Market by Technology
- 5.1.4.3.2 Mexico Companion Diagnostics Market by Indication
- 5.1.4.4 Rest of North America Companion Diagnostics Market
- 5.1.4.4.1 Rest of North America Companion Diagnostics Market by Technology
- 5.1.4.4.2 Rest of North America Companion Diagnostics Market by Indication
- 5.2 Europe Companion Diagnostics Market
- 5.2.1 Europe Companion Diagnostics Market by Technology
- 5.2.1.1 Europe Immunohistochemistry Market by Country
- 5.2.1.2 Europe Polymerase chain reaction (PCR) Market by Country
- 5.2.1.3 Europe Next generation sequencing (NGS) Market by Country
- 5.2.1.4 Europe In Situ Hybridization Market by Country
- 5.2.1.5 Europe Other Technology Market by Country
- 5.2.2 Europe Companion Diagnostics Market by Indication
- 5.2.2.1 Europe Oncology Companion Diagnostics Market by Country
- 5.2.2.2 Europe Neurology Companion Diagnostics Market by Country
- 5.2.2.3 Europe Other Indications Companion Diagnostics Market by Country
- 5.2.2.4 Europe Companion Diagnostics Market by Cancer Type
- 5.2.2.4.1 Europe Breast Cancer Companion Diagnostics by Country
- 5.2.2.4.2 Europe Colorectal Cancer Companion Diagnostics by Country
- 5.2.2.4.3 Europe Lung Cancer Companion Diagnostics by Country
- 5.2.2.4.4 Europe Blood Cancer Companion Diagnostics by Country
- 5.2.2.4.5 Europe Other Cancer Type Companion Diagnostics Market by Country
- 5.2.3 Europe Companion Diagnostics Market by Country
- 5.2.3.1 Germany Companion Diagnostics Market
- 5.2.3.1.1 Germany Companion Diagnostics Market by Technology
- 5.2.3.1.2 Germany Companion Diagnostics Market by Indication
- 5.2.3.2 UK Companion Diagnostics Market
- 5.2.3.2.1 UK Companion Diagnostics Market by Technology
- 5.2.3.2.2 UK Companion Diagnostics Market by Indication
- 5.2.3.3 France Companion Diagnostics Market
- 5.2.3.3.1 France Companion Diagnostics Market by Technology
- 5.2.3.3.2 France Companion Diagnostics Market by Indication
- 5.2.3.4 Russia Companion Diagnostics Market
- 5.2.3.4.1 Russia Companion Diagnostics Market by Technology
- 5.2.3.4.2 Russia Companion Diagnostics Market by Indication
- 5.2.3.5 Spain Companion Diagnostics Market
- 5.2.3.5.1 Spain Companion Diagnostics Market by Technology
- 5.2.3.5.2 Spain Companion Diagnostics Market by Indication
- 5.2.3.6 Italy Companion Diagnostics Market
- 5.2.3.6.1 Italy Companion Diagnostics Market by Technology
- 5.2.3.6.2 Italy Companion Diagnostics Market by Indication
- 5.2.3.7 Rest of Europe Companion Diagnostics Market
- 5.2.3.7.1 Rest of Europe Companion Diagnostics Market by Technology
- 5.2.3.7.2 Rest of Europe Companion Diagnostics Market by Indication
- 5.3 Asia Pacific Companion Diagnostics Market
- 5.3.1 Asia Pacific Companion Diagnostics Market by Technology
- 5.3.1.1 Asia Pacific Immunohistochemistry Market by Country
- 5.3.1.2 Asia Pacific Polymerase chain reaction (PCR) Market by Country
- 5.3.1.3 Asia Pacific Next generation sequencing (NGS) Market by Country
- 5.3.1.4 Asia Pacific In Situ Hybridization Market by Country
- 5.3.1.5 Asia Pacific Other Technology Market by Country
- 5.3.2 Asia Pacific Companion Diagnostics Market by Indication
- 5.3.2.1 Asia Pacific Oncology Companion Diagnostics Market by Country
- 5.3.2.2 Asia Pacific Neurology Companion Diagnostics Market by Country
- 5.3.2.3 Asia Pacific Other Indications Companion Diagnostics Market by Country
- 5.3.2.4 Asia Pacific Companion Diagnostics Market by Cancer Type
- 5.3.2.4.1 Asia Pacific Breast Cancer Companion Diagnostics by Country
- 5.3.2.4.2 Asia Pacific Colorectal Cancer Companion Diagnostics by Country
- 5.3.2.4.3 Asia Pacific Lung Cancer Companion Diagnostics by Country
- 5.3.2.4.4 Asia Pacific Blood Cancer Companion Diagnostics by Country
- 5.3.2.4.5 Asia Pacific Other Cancer Type Companion Diagnostics Market by Country
- 5.3.3 Asia Pacific Companion Diagnostics Market by Country
- 5.3.3.1 China Companion Diagnostics Market
- 5.3.3.1.1 China Companion Diagnostics Market by Technology
- 5.3.3.1.2 China Companion Diagnostics Market by Indication
- 5.3.3.2 Japan Companion Diagnostics Market
- 5.3.3.2.1 Japan Companion Diagnostics Market by Technology
- 5.3.3.2.2 Japan Companion Diagnostics Market by Indication
- 5.3.3.3 India Companion Diagnostics Market
- 5.3.3.3.1 India Companion Diagnostics Market by Technology
- 5.3.3.3.2 India Companion Diagnostics Market by Indication
- 5.3.3.4 Australia Companion Diagnostics Market
- 5.3.3.4.1 Australia Companion Diagnostics Market by Technology
- 5.3.3.4.2 Australia Companion Diagnostics Market by Indication
- 5.3.3.5 South Korea Companion Diagnostics Market
- 5.3.3.5.1 South Korea Companion Diagnostics Market by Technology
- 5.3.3.5.2 South Korea Companion Diagnostics Market by Indication
- 5.3.3.6 Singapore Companion Diagnostics Market
- 5.3.3.6.1 Singapore Companion Diagnostics Market by Technology
- 5.3.3.6.2 Singapore Companion Diagnostics Market by Indication
- 5.3.3.7 Rest of Asia Pacific Companion Diagnostics Market
- 5.3.3.7.1 Rest of Asia Pacific Companion Diagnostics Market by Technology
- 5.3.3.7.2 Rest of Asia Pacific Companion Diagnostics Market by Indication
- 5.4 LAMEA Companion Diagnostics Market
- 5.4.1 LAMEA Companion Diagnostics Market by Technology
- 5.4.1.1 LAMEA Immunohistochemistry Market by Country
- 5.4.1.2 LAMEA Polymerase chain reaction (PCR) Market by Country
- 5.4.1.3 LAMEA Next generation sequencing (NGS) Market by Country
- 5.4.1.4 LAMEA In Situ Hybridization Market by Country
- 5.4.1.5 LAMEA Other Technology Market by Country
- 5.4.2 LAMEA Companion Diagnostics Market by Indication
- 5.4.2.1 LAMEA Oncology Companion Diagnostics Market by Country
- 5.4.2.2 LAMEA Neurology Companion Diagnostics Market by Country
- 5.4.2.3 LAMEA Other Indications Companion Diagnostics Market by Country
- 5.4.2.4 LAMEA Companion Diagnostics Market by Cancer Type
- 5.4.2.4.1 LAMEA Breast Cancer Companion Diagnostics by Country
- 5.4.2.4.2 LAMEA Colorectal Cancer Companion Diagnostics by Country
- 5.4.2.4.3 LAMEA Lung Cancer Companion Diagnostics by Country
- 5.4.2.4.4 LAMEA Blood Cancer Companion Diagnostics by Country
- 5.4.2.4.5 LAMEA Other Cancer Type Companion Diagnostics Market by Country
- 5.4.3 LAMEA Companion Diagnostics Market by Country
- 5.4.3.1 Brazil Companion Diagnostics Market
- 5.4.3.1.1 Brazil Companion Diagnostics Market by Technology
- 5.4.3.1.2 Brazil Companion Diagnostics Market by Indication
- 5.4.3.2 Argentina Companion Diagnostics Market
- 5.4.3.2.1 Argentina Companion Diagnostics Market by Technology
- 5.4.3.2.2 Argentina Companion Diagnostics Market by Indication
- 5.4.3.3 UAE Companion Diagnostics Market
- 5.4.3.3.1 UAE Companion Diagnostics Market by Technology
- 5.4.3.3.2 UAE Companion Diagnostics Market by Indication
- 5.4.3.4 Saudi Arabia Companion Diagnostics Market
- 5.4.3.4.1 Saudi Arabia Companion Diagnostics Market by Technology
- 5.4.3.4.2 Saudi Arabia Companion Diagnostics Market by Indication
- 5.4.3.5 South Africa Companion Diagnostics Market
- 5.4.3.5.1 South Africa Companion Diagnostics Market by Technology
- 5.4.3.5.2 South Africa Companion Diagnostics Market by Indication
- 5.4.3.6 Nigeria Companion Diagnostics Market
- 5.4.3.6.1 Nigeria Companion Diagnostics Market by Technology
- 5.4.3.6.2 Nigeria Companion Diagnostics Market by Indication
- 5.4.3.7 Rest of LAMEA Companion Diagnostics Market
- 5.4.3.7.1 Rest of LAMEA Companion Diagnostics Market by Technology
- 5.4.3.7.2 Rest of LAMEA Companion Diagnostics Market by Indication
Chapter 6. Company Profiles
- 6.1 Agilent Technologies, Inc.
- 6.1.1 Company Overview
- 6.1.2 Financial Analysis
- 6.1.3 Segmental and Regional Analysis
- 6.1.4 Research & Development Expense
- 6.1.5 Recent strategies and developments:
- 6.1.5.1 Product launches:
- 6.1.5.2 Expansions:
- 6.2 Almac Group
- 6.2.1 Company Overview
- 6.2.1 Recent strategies and developments:
- 6.2.1.1 Collaborations, partnerships and agreements:
- 6.3 ARUP Laboratories, Inc.
- 6.4 Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- 6.4.1 Company Overview
- 6.4.2 Financial Analysis
- 6.4.3 Segmental and Regional Analysis
- 6.4.4 Research & Development Expense
- 6.5 Danaher Corporation
- 6.5.1 Company Overview
- 6.5.2 Financial Analysis
- 6.5.3 Segmental and Regional Analysis
- 6.5.4 Research & Development Expense
- 6.5.5 Recent strategies and developments:
- 6.5.5.1 Acquisition and mergers:
- 6.6 Thermo Fischer Scientific, Inc.
- 6.6.1 Company Overview
- 6.6.2 Financial Analysis
- 6.6.3 Segmental and Regional Analysis
- 6.6.4 Research & Development Expense
- 6.6.5 Recent strategies and developments:
- 6.6.5.1 Collaborations, partnerships and agreements:
- 6.6.5.2 Expansions:
- 6.7 Hologic, Inc.
- 6.7.1 Company Overview
- 6.7.2 Financial Analysis
- 6.7.3 Segmental and Regional Analysis
- 6.7.4 Research & Development Expense
- 6.7.5 Recent strategies and developments:
- 6.7.5.1 Product launches:
- 6.7.5.2 Acquisition and mergers:
- 6.8 Novartis AG
- 6.8.1 Company Overview
- 6.8.2 Financial Analysis
- 6.8.3 Segmental and Regional Analysis
- 6.8.4 Research & Development Expense
- 6.8.5 Recent strategies and developments:
- 6.8.5.1 Collaborations, partnerships and agreements:
- 6.9 Illumina, Inc.
- 6.9.1 Company Overview
- 6.9.2 Financial Analysis
- 6.9.3 Regional Analysis
- 6.9.4 Research & Development Expense
- 6.9.5 Recent strategies and developments:
- 6.9.5.1 Product launches:
- 6.9.5.2 Acquisition and mergers:
- 6.9.5.3 Collaborations, partnerships and agreements:
- 6.1 Qiagen N.V.
- 6.10.1 Company Overview
- 6.10.2 Financial Analysis
- 6.10.3 Regional Analysis
- 6.10.4 Research & Development Expense
- 6.10.5 Recent strategies and developments:
- 6.10.5.1 Product launches:
- 6.10.5.2 Collaborations, partnerships and agreements:
